Clinical Advances in Hematology & Oncology最新文献_第3页

Highlights in chronic lymphocytic leukemia from the 66th ASH Annual Meeting and Exposition. 第 66 届 ASH 年会暨博览会上的慢性淋巴细胞白血病亮点。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-02-01

引用次数: 0

The role of CTLA-4 inhibition in immunotherapy for MSI-H/dMMR metastatic colorectal cancer. CTLA-4 抑制剂在 MSI-H/dMMR 转移性结直肠癌免疫疗法中的作用。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-01-01

Christina S Wu

引用次数: 0

Chimeric antigen receptor T-cell therapy for T-cell acute lymphocytic leukemia. t细胞急性淋巴细胞白血病的嵌合抗原受体t细胞治疗。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-01-01

Ibrahim Aldoss

引用次数: 0

Management of oligoprogressive and oligopersistent disease in advanced NSCLC. 晚期非小细胞肺癌低进行性和低持续性疾病的治疗。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-01-01

Revathi Ravella, Erin Jay G Feliciano, Edward Christopher Dee, Daniel R Gomez, Puneeth Iyengar

{"title":"Management of oligoprogressive and oligopersistent disease in advanced NSCLC.","authors":"Revathi Ravella, Erin Jay G Feliciano, Edward Christopher Dee, Daniel R Gomez, Puneeth Iyengar","doi":"","DOIUrl":"","url":null,"abstract":"The oligometastatic disease state is defined as an intermediate state between localized cancer and widespread systemic metastases. Oligoprogression is defined as a subgroup in which limited metastatic areas are progressing in the background of oligometastatic or polymetastatic disease, whereas oligopersistent disease refers to an induced state in which formerly polymetastatic disease responds to treatment and decreases to fewer than 5 sites of active disease. With modern improvements in systemic therapy for patients with non-small cell lung cancer, including immunotherapies and targeted therapies, there may be a role for local therapy in selected patients with limited metastases-a subset of patients with potentially curable metastatic disease. Improved imaging techniques and advancements in highly conformal delivery of radiotherapy with stereotactic body radiation therapy have increased interest in using ablative radiotherapy or surgery as local consolidation therapy to improve patient outcomes. In this review, we define the oligoprogressive and oligopersistent disease states in patients with non-small cell lung cancer and discuss the evidence for the treatment and management of this patient population, including recent prospective trials and future directions in the selection of patients who will benefit most from local therapy.","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 1","pages":"40-50"},"PeriodicalIF":1.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Personalized approaches to breast radiotherapy: strategies for treatment refinement. 乳腺放射治疗的个性化方法：完善治疗的策略。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-01-01

Diana A Roth O'Brien, Lior Z Braunstein

{"title":"Personalized approaches to breast radiotherapy: strategies for treatment refinement.","authors":"Diana A Roth O'Brien, Lior Z Braunstein","doi":"","DOIUrl":"","url":null,"abstract":"Radiotherapy (RT) is a crucial component of the adjuvant treatment of breast cancer that often follows breast conservation or mastectomy to further reduce the risk of local recurrence. As outcomes improve and our understanding of disease biology advances, interest is growing in de-escalating RT to minimize the treatment burden and side effects while maintaining oncologic outcomes. This review examines the evidence and summarizes the results of ongoing trials evaluating RT de-escalation strategies in breast cancer. We discuss hypofractionation and ultrahypofractionation for whole breast irradiation, showing efficacy comparable with that of conventional fractionation with improved convenience. The role of accelerated partial breast irradiation is explored, with an emphasis on its benefits and the importance of patient selection. We review data supporting omission of RT in selected patients with low-risk, early-stage disease, particularly older women with hormone receptor-positive disease. Ongoing research into biomarker-guided RT de-escalation is addressed, including trials using genomic assays and immunohistochemistry. Emerging data on RT de-escalation in HER2-positive and triple-negative breast cancers are discussed. Finally, we explore de-escalation strategies for locally advanced disease, including hypofractionation for post-mastectomy RT and potential omission of regional nodal irradiation after neoadjuvant chemotherapy for those with an excellent response. These strategies may allow more personalized approaches to RT, potentially improving quality of life without compromising oncologic outcomes.","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 1","pages":"30-39"},"PeriodicalIF":1.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel approaches to optimization of drug dosages. 优化药物剂量的新方法。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-01-01

Charles F Manski

引用次数: 0

Is MRD testing ready for general use in chronic lymphocytic leukemia? MRD检测在慢性淋巴细胞白血病中的普遍应用准备好了吗？

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-01-01

Carolyn Owen

引用次数: 0

New cell surface targets in prostate cancer. 前列腺癌的新细胞表面靶点。